- Home
- SNPX vs SBFM Comparison
SNPX vs SBFM Comparison
Compare SNPX & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNPX
- SBFM
- Stock Information
- Founded
- SNPX 2012
- SBFM 2006
- Country
- SNPX United States
- SBFM United States
- Employees
- SNPX 5
- SBFM N/A
- Industry
- SNPX Medicinal Chemicals and Botanical Products
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- SNPX Health Care
- SBFM Health Care
- Exchange
- SNPX Nasdaq
- SBFM Nasdaq
- Market Cap
- SNPX 3.7M
- SBFM 3.7M
- IPO Year
- SNPX N/A
- SBFM N/A
- Fundamental
- Price
- SNPX $2.69
- SBFM $2.78
- Analyst Decision
- SNPX Strong Buy
- SBFM Strong Buy
- Analyst Count
- SNPX 1
- SBFM 1
- Target Price
- SNPX $14.00
- SBFM $15.00
- AVG Volume (30 Days)
- SNPX 13.4K
- SBFM 1.8M
- Earning Date
- SNPX 11-12-2024
- SBFM 11-05-2024
- Dividend Yield
- SNPX N/A
- SBFM N/A
- EPS Growth
- SNPX N/A
- SBFM N/A
- EPS
- SNPX N/A
- SBFM N/A
- Revenue
- SNPX N/A
- SBFM $32,959,491.00
- Revenue This Year
- SNPX N/A
- SBFM $86.70
- Revenue Next Year
- SNPX N/A
- SBFM $126.76
- P/E Ratio
- SNPX N/A
- SBFM N/A
- Revenue Growth
- SNPX N/A
- SBFM 61.94
- 52 Week Low
- SNPX $2.32
- SBFM $2.11
- 52 Week High
- SNPX $8.78
- SBFM $608.00
- Technical
- Relative Strength Index (RSI)
- SNPX 45.01
- SBFM 47.83
- Support Level
- SNPX $2.52
- SBFM $2.51
- Resistance Level
- SNPX $2.80
- SBFM $2.82
- Average True Range (ATR)
- SNPX 0.21
- SBFM 0.29
- MACD
- SNPX -0.01
- SBFM -0.02
- Stochastic Oscillator
- SNPX 33.32
- SBFM 22.34
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.